CN114269345B - Alk2抑制剂的晶体形式 - Google Patents
Alk2抑制剂的晶体形式 Download PDFInfo
- Publication number
- CN114269345B CN114269345B CN201980086179.8A CN201980086179A CN114269345B CN 114269345 B CN114269345 B CN 114269345B CN 201980086179 A CN201980086179 A CN 201980086179A CN 114269345 B CN114269345 B CN 114269345B
- Authority
- CN
- China
- Prior art keywords
- bmp
- compound
- crystalline compounds
- activity
- compositions described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751255P | 2018-10-26 | 2018-10-26 | |
| US62/751255 | 2018-10-26 | ||
| PCT/US2019/058062 WO2020086963A1 (en) | 2018-10-26 | 2019-10-25 | Crystal forms of an alk2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114269345A CN114269345A (zh) | 2022-04-01 |
| CN114269345B true CN114269345B (zh) | 2025-06-27 |
Family
ID=70330555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980086179.8A Active CN114269345B (zh) | 2018-10-26 | 2019-10-25 | Alk2抑制剂的晶体形式 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12071438B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870181B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7504880B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114269345B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019364631B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117695A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020086963A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202103228B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| EP4294403A4 (en) * | 2021-02-18 | 2024-12-11 | Beren Therapeutics P.B.C. | METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018200855A1 (en) * | 2017-04-27 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20190055192A1 (en) | 2004-06-07 | 2019-02-21 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| DE602005023763D1 (de) * | 2004-11-04 | 2010-11-04 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| EP2954903A1 (en) | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| US7790407B2 (en) | 2005-11-29 | 2010-09-07 | Nevada Cancer Institute | Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| CN105503882B (zh) * | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| EP2964651A4 (en) | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
| JP6542192B2 (ja) * | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Bmp阻害剤およびその使用方法 |
| CA2904357C (en) | 2013-03-15 | 2020-09-22 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| MX2020005405A (es) | 2017-11-24 | 2020-08-13 | Novartis Ag | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| AU2019364415A1 (en) | 2018-10-23 | 2021-05-20 | Keros Therapeutics, Inc. | ALK2 antibodies and methods of use thereof |
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| MX2022001741A (es) | 2019-08-13 | 2022-03-11 | Blueprint Medicines Corp | Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina. |
| WO2021067670A1 (en) | 2019-10-02 | 2021-04-08 | Blueprint Medicines Corporation | Process for preparing an activin receptor-like kinase inhibitor |
| TW202131926A (zh) | 2019-11-22 | 2021-09-01 | 美商英塞特公司 | 包含alk2抑制劑及jak2抑制劑的組合療法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022098821A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating lymphopenia |
| WO2022099166A1 (en) | 2020-11-09 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating cardiovascular-related disease |
| US20250034148A1 (en) | 2021-11-02 | 2025-01-30 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
-
2019
- 2019-10-25 CA CA3117695A patent/CA3117695A1/en active Pending
- 2019-10-25 EP EP19877275.8A patent/EP3870181B1/en active Active
- 2019-10-25 CN CN201980086179.8A patent/CN114269345B/zh active Active
- 2019-10-25 AU AU2019364631A patent/AU2019364631B2/en active Active
- 2019-10-25 JP JP2021522993A patent/JP7504880B2/ja active Active
- 2019-10-25 WO PCT/US2019/058062 patent/WO2020086963A1/en not_active Ceased
-
2021
- 2021-04-23 US US17/238,986 patent/US12071438B2/en active Active
- 2021-05-12 ZA ZA2021/03228A patent/ZA202103228B/en unknown
-
2024
- 2024-06-12 JP JP2024094803A patent/JP2024107352A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018200855A1 (en) * | 2017-04-27 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Novel alk2 inhibitors and methods for inhibiting bmp signaling |
Also Published As
| Publication number | Publication date |
|---|---|
| US12071438B2 (en) | 2024-08-27 |
| AU2019364631B2 (en) | 2025-05-01 |
| ZA202103228B (en) | 2025-08-27 |
| WO2020086963A1 (en) | 2020-04-30 |
| JP2024107352A (ja) | 2024-08-08 |
| EP3870181B1 (en) | 2024-08-14 |
| CA3117695A1 (en) | 2020-04-30 |
| JP7504880B2 (ja) | 2024-06-24 |
| AU2019364631A1 (en) | 2021-06-03 |
| JP2022512824A (ja) | 2022-02-07 |
| US20210238185A1 (en) | 2021-08-05 |
| EP3870181A4 (en) | 2022-07-20 |
| EP3870181A1 (en) | 2021-09-01 |
| CN114269345A (zh) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7504880B2 (ja) | Alk2阻害剤の結晶形 | |
| US10583143B2 (en) | Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue | |
| CN111164083B (zh) | 用于抑制bmp信号传导的新型alk2抑制剂和方法 | |
| KR102092988B1 (ko) | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 | |
| EA032596B1 (ru) | Соли, способ их получения и их применение для лечения воспалительных заболеваний | |
| JP2016510745A (ja) | Bmp阻害剤およびその使用方法 | |
| JP2014504604A (ja) | 心血管疾患のための組成物および方法 | |
| US8883763B2 (en) | Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same | |
| CN106536520A (zh) | 芳基受体调制剂及其制备和使用方法 | |
| PT2663564E (pt) | Composto de imidazo[4,5-c]quinolin-2-ona e a sua utilização como inibidor dual de quinase pi3/mtor | |
| JP2023516645A (ja) | Tead阻害剤としてのヘテロ二官能性分子 | |
| EP4236941A1 (en) | Nmt inhibitors for treating senescence-associated diseases or disorders | |
| US20100099106A1 (en) | Cell death inhibitor | |
| WO2018053373A1 (en) | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis | |
| CA3078247A1 (en) | Methods and compositions for treating urea cycle disorders, in particular otc deficiency | |
| JP6553081B2 (ja) | アダプター関連キナーゼ1の阻害剤、それを含む組成物、及びその使用方法 | |
| JP6909236B2 (ja) | キナゾリン誘導体またはその塩およびそれを含む医薬組成物 | |
| CN121079296A (zh) | α-v-β-8整合素抑制剂及其用途 | |
| CN111108083B (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
| EP3475274A1 (en) | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | |
| US9273006B2 (en) | Anabolic compounds for treating and preventing bone loss diseases | |
| AU2007223865A1 (en) | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders | |
| EA028800B1 (ru) | Комбинация производного имидазопиридазина и митотического средства для лечения рака | |
| EP3706776A1 (en) | Immunogenic compositions and uses therefor | |
| JP2021031455A (ja) | Ifitm5の変異に起因する骨形成不全症を治療するための医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |